Haemin Chon
Vice President & Head, Convergence R&D Center Hanmi Pharm
Haemin Chon (PhD) is a translational researcher devoting on drug development for 5 years with both clinical and basic research backgrounds. His technological basis is multi-omics study, bioinformatics, biomedical statistics, and in vitro and in vivo studies. Areas of interest are neuroscience, metabolic diseases, oncology, rare diseases, and longevity science. Outcomes Haemin has generated include seeking biomarkers, elucidating mechanism of action, designate right indication, and drafting clinical development strategies for innovative new drugs. In the context of drug development process, he has experiences in target validation, hit discovery, lead optimization, efficacy evaluation, toxicity evaluation, and early clinical development. Drug modalities such as small molecule, peptide, oligonucleotide, mRNA, and TPD are consisting his experience landscape.
Seminars
- Understanding the state-of-play of AI/ML and computational methods across in silico drug design and complementary integration to improve quality and timelines of drug discovery workflows
- Evaluating applications of AI/ML showing promise through experimental validation and dealmaking versus discovery use cases that remain challenging
- Debating global attitudes and the best approaches to foster global discovery collaborations, highlighting the importance of experimental validation and access to quality data resources
- Contextualizing the mismatch between discovery, preclinical, and translational research in drug development and the lack of reliable AI and business intelligence solutions for these domains
- Laying out Hanmi Pharm’s expertise in peptide drug design, biomarker-driven indication prioritization, and animal-to-human translational research
- Assessing the current impact and future potential of AI/BI-driven productivity enhancement across discovery, preclinical and translational research
